An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
about
Human immunodeficiency virus & cardiovascular riskAntiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasiaRisk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics.A Review of the Literature Concerning HIV and Cigarette Smoking: Morbidity and Mortality, Associations with Individual- and Social-Level Characteristics, and Smoking Cessation Efforts.Heart and HAART: Two sides of the coin for HIV-associated cardiology issuesChromium Therapy for Insulin Resistance Associated with HIV-DiseaseRisk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewCigarette smoking in the HIV-infected population.Clinical Outcomes of Patients with HIV Undergoing Lead Extraction for Infectious and Noninfectious Indications.Update on HIV lipodystrophy.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Interrupting highly active antiretroviral therapy in patients with HIV.Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS.HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.Long-Term Cigarette Smoking Trajectories Among HIV-Seropositive and Seronegative MSM in the Multicenter AIDS Cohort StudyCardiovascular effects of noncardiovascular drugs.The Relationship Between HIV Infection and Cardiovascular Disease.Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.Smoking and HIV: prevalence, health risks, and cessation strategies.Nutrition and the HIV-associated lipodystrophy syndrome.A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea.Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant.Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries.Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study.Atherosclerosis and central adiposity in a pediatric patient with AIDS treated with HAART: autopsy findings.Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution.Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets
P2860
Q22241184-5774C5FF-240B-49D7-8A93-CF86F4F31813Q30430542-1AAEB00C-11A4-4CC8-8D95-ED687A920F4EQ33603728-2942CC06-0EDC-4159-A899-BC0CD3C2970CQ33680718-27AAF6FD-E3EC-4E51-B503-81858F591431Q33704159-231D1E0E-7D9D-482E-879F-AE1DE6D6403DQ34390565-11B258D2-F545-4A2C-A12E-45441EA336EBQ34390688-C961DAFF-A5F5-4EB6-AD94-66144BEBDAD0Q34651525-ABFAFD78-F3B2-4E9B-97E2-41319ADE41A5Q35095054-6C470FA3-730F-4C31-BC00-ED99F2406B4EQ35826419-F43E1FAB-5371-44FD-B3B3-8BF0859E5AA0Q35833512-5655322E-A5FE-4516-A1E0-CFE6A505D2B4Q36011828-3BA98781-E9DD-4E07-9F63-8D4139FFA5BDQ36066209-98924B39-AE10-44CB-8AE7-229522F27B4AQ36554948-B1A70389-801F-4C46-A612-ACAD02ED22CFQ36773367-817FB824-1F61-4267-93B5-A607EABE9CD3Q36942884-3CE2C808-5DF1-4B83-B3BC-D0D339B0B84CQ37095694-AFE906A5-A50D-4C5F-8DCC-E8421830D208Q37413163-8FAED74E-01D0-4DB9-8C31-92A7DF036FAAQ37429096-6813B66B-0017-4C69-9DD2-3C11FCE2A3A5Q37993138-F5FB4C93-BB39-46AB-9B75-26AF8B01CF28Q38012348-9E3EB1FE-1057-487E-A194-A2229EAF776BQ38061798-AB294E24-8D08-4BA3-AD4E-E52AD52E702DQ42275051-B19D3CA1-7D88-4890-B50F-38DB79A5B8E5Q44573324-6A35CA0F-DFC2-4A03-962A-EFFAFBC08966Q45244983-56A99EB6-4FC8-41C8-82C8-20322F8416B8Q46665887-FADC1CDB-BDC9-442A-9684-52D6E32AFE47Q46812196-923A2067-287D-417A-BA20-971D521D37A9Q48340174-D958BB3B-D06B-42B3-B26F-A9B10A97F6FBQ50925529-CF9C3FFA-9652-4B48-81F1-2B09B0E73B36Q51300376-89039366-56D5-4579-90B8-F701CF78DD75Q55210420-A87B71C5-71F1-4576-99E5-BF056641E35BQ57259689-03D74153-06B9-4C4A-9F04-F46CE3969987
P2860
An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
An open-label, prospective, ob ...... active antiretroviral therapy.
@en
An open-label, prospective, ob ...... active antiretroviral therapy.
@nl
type
label
An open-label, prospective, ob ...... active antiretroviral therapy.
@en
An open-label, prospective, ob ...... active antiretroviral therapy.
@nl
prefLabel
An open-label, prospective, ob ...... active antiretroviral therapy.
@en
An open-label, prospective, ob ...... active antiretroviral therapy.
@nl
P2093
P1476
An open-label, prospective, ob ...... active antiretroviral therapy.
@en
P2093
Alfio Lucchini
Augusto Cirelli
Benvenuto Grisorio
Christine Hazra
Gabriella Di Lorenzo
Giorgio Barbarini
Giuseppe Barbaro
P304
P356
10.1016/S0149-2918(03)80283-7
P577
2003-09-01T00:00:00Z